With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.25137-01-3,(R)-Ethyl piperidine-3-carboxylate,as a common compound, the synthetic route is as follows.
To a mixture of (R)-ethyl nipecotate (1.15 g) and tetrahydrofuran (16 ml) was added lithium aluminum hydride (278 mg) at 0C. The mixture was stirred for 3 hours with elevating the temperature to room temperature. Water (0.28 ml), 25% potassium hydroxide solution (0.28 ml) and brine (0.84 ml) were added thereto in this order, and the mixture was stirred for 15 hours. The insolubles were filtered off using celite and the mother liquor was concentrated, to give (R)-3-(hydroxymethyl)piperidine (852 mg). [alpha]D = +11.7 (c = 0.730, MeOH). 1H-NMR (300 Hz, CDCl3) delta: 1.07-1.20 (1H, m), 1.40-1.54 (1H, m), 1.61-1.82 (3H, m), 2.39 (1H, dd, J=12.0 and 9.9 Hz), 2.54-2.62 (3H, m), 2.95-3.01 (1H, m), 3.13-3.18 (1H, m), 3.40-3.54 (2H, m).
25137-01-3, The synthetic route of 25137-01-3 has been constantly updated, and we look forward to future research findings.
Reference：
Patent; Takeda Pharmaceutical Company Limited; EP1553074; (2005); A1;,
Piperidine – Wikipedia
Piperidine | C5H11N – PubChem